排序方式: 共有33条查询结果,搜索用时 46 毫秒
1.
目的观察胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)类似物对2型糖尿病早期肾病患者的肾脏保护作用。方法2017年11月—2019年12月间选取使用GLP-1类似物并参与随访的2型糖尿病早期肾病患者30例,收集患者治疗6个月前后的体重,体质指数(body mass index,BMI),腰围,臀围,血糖,生化指标等,计算胰岛β细胞功能相关指标,进行对比分析。结果治疗后腰围、2 hPG、HbA1c、HOMA-IR、TC、TG、ALB、MA/Cr、UA较治疗前降低,HOMA-β较治疗前升高,差异有统计学意义(P<0.05)。Pearson相关性分析示:HbA1c与MA/Cr呈负相关性(r=-0.421,P<0.05);HOMA-β、TG、TC、UA与MA/Cr呈正相关性(r=0.777,P<0.05;r=0.757,P<0.05;r=0.470,P<0.05;r=0.443,P<0.05)。HbA1c与ALB呈负相关性(r=-0.433,P<0.05);HOMA-β、TG、TC、UA与ALB呈正相关性(r=0.723,P<0.05;r=0.756,P<0.05;r=0.493,P<0.05;r=0.374,P<0.05)。结论GLP-1类似物对2型糖尿病早期肾病患者有较好的降糖、调脂、改善胰岛功能、保护肾脏的作用,而且降血糖、降血脂、改善胰岛功能可能有益于肾脏保护。 相似文献
2.
目的 分析BP与T2DM患者尿白蛋白/肌酐(UACR)的关系,探讨BP对糖尿病慢性肾脏疾病(CKD)的影响. 方法 收集330例T2DM患者资料,测BP和UACR.根据UACR水平分为<30mg/24 h组、30~299mg/24 h组和≥300mg/24 h组,检测各组BP及UACR等水平的变化情况.结果 正常血压组及高血压组蛋白尿发生率为31.4%及64.2%.病程<10年、病程10~20年及病程>20年正常血压者与高血压者比较,总蛋白尿的发生率分别为0%、8%,7.6%、30.1%,0%及51.7%(P<0.01).UACR<30 mg/24 h组、≥300mg/24 h组高血压发生率为30.3%及69.1%;病程<10年、病程10~20年及病程>20年患者中<30mg/24 h组、30~299mg/24 h组和≥300mg/24 h组比较,高血压发生率分别为28.9%、67.4%、100%,33.3%、50.9%、76.7%,25.0%、84.6%和100% (P<0.01). 结论 高血压加速CKD的发生. 相似文献
3.
4.
Disha Mehta Daniela A. Pimentel Maria-Zunilda Núñez Amir Abduljalil Vera Novak 《Metabolism: clinical and experimental》2014
Objective
Microalbuminuria (MA), a marker of renal microvascular disease, is associated with brain atrophy and neurovascular changes in older adults with type 2 diabetes mellitus (DM). We evaluated the relationship between urine albumin-to-creatinine ratio (UACR) and regional brain volumes to determine whether subclinical albuminuria may indicate early structural brain changes in type 2 DM.Materials/Methods
We studied UACR and brain volumes in 85 type 2 DM patients (64.8 ± 8.3 years) and 40 age-matched controls using 3D magnetization prepared rapid acquisition with gradient echo (MP-RAGE) MRI (magnetic resonance imaging) at 3 Tesla. The relationship between UACR and brain volumes was analyzed using the least square models.Results
In DM patients, UACR ≥ 5 mg/g, UACR ≥ 10 mg/g and clinically significant MA (UACR ≥ 17 mg/g [males] and 25 mg/g [females]) were associated with lower gray matter (GM) volume in the frontal lobe (r2adj = 0.2–0.4, P = 0.01–0.05) and UACR ≥ 5 mg/g was also related to global GM atrophy (r2adj = 0.1, P = 0.04), independent of DM duration, glucose levels, HbA1c and hypertension. For UACR ≥ 5 mg/g, a lower global GM volume was related to worse executive function (P = 0.04) in the DM group. No associations were found for UACR (< 5 mg/g) and controls.Conclusions
Subclinical albuminuria (UACR ≥ 5 mg/g) is associated with lower GM volume that has clinical impact on cognitive function in older diabetic patients, and these relationships are independent of DM control and hypertension. Therefore, UACR levels may serve as an additional marker of DM-related brain structural changes. 相似文献5.
目的分析β2-MG、UACR及Cys-C对原发性老年高血压肾损伤的预测价值研究。方法选取2017年1月至2020年1月本院接收的90例原发性老年高血压患者临床资料,为研究组,根据是否合并肾损伤分为两组,将合并肾损伤者设为A组(n=52)例,将未合并肾损伤者设为B组(n=38)例;同时选取64例同期健康体检人群作为对照组。对比不同人群β2-MG、UACR及Cys-C水平;采用多元Logistic回归分析影响原发性老年高血压合并肾损伤的独立危险因素;应用ROC曲线分析β2-MG、UACR及Cys-C对原发性老年高血压合并肾损伤的预测价值。结果研究组患者β2-MG、UACR及Cys-C水平高于对照组,差异有统计学意义(P<0.05);A组患者β2-MG、UACR及Cys-C水平高于B组,差异有统计学意义(P<0.05);通过Logistic回归模型分析影响原发性老年高血压合并肾损伤的相关因素,得出:收缩压、舒张压、β2-MG、UACR、Cys-C、血脂异常为影响原发性老年高血压合并肾损伤的单因素(P<0.05),进一步分析发现舒张压异常、收缩压异常、β2-MG、UACR、Cys-C异常升高为影响原发性老年高血压合并肾损伤的独立危险因素(P<0.05);β2-MG、UACR、Cys-C及三者联合约登指数分别为0.626、0.638、0.624、0.788;β2-MG、UACR、Cys-C及三者联合曲线下面积分别为0.699、0.821、0.712、0.923,各指标曲线下面积以联合检测最大。结论β2-MG、UACR及Cys-C水平异常是影响原发性老年高血压合并肾损伤的独立危险因素,联合指标检测对评估患者病情有重要价值。 相似文献
6.
Efaza U. Siddiqui Timothy P. Murphy Syed S. Naeem Ayesha Siddique Gregory E. McEnteggart Roberto Scarpioni 《Journal of vascular and interventional radiology : JVIR》2018,29(7):966-970
Purpose
To perform a post-hoc analysis of the Nephropathy Ischemic Therapy (NITER) trial, which enrolled patients with atherosclerotic renal artery stenosis, to evaluate whether medical therapy plus stent placement is superior to medical therapy alone in patients without elevated albuminuria.Materials and Methods
Data from 51 patients were analyzed and stratified into 2 cohorts by median urinary albumin (UAlb) levels: cohort 1 (“low albuminuria,” UAlb ≤0.04 g/24h) and cohort 2 (“high albuminuria,” UAlb >0.04g/24h). Interaction effect between treatment arms and UAlb cohorts was calculated using Cox regression analysis. Survival analysis was followed by test for effect size, power analysis, and construction of a Kaplan-Meier survival table.Results
At study completion, 13 patients had an outcome event: 6 (23%) from cohort 1 and 7 (28%) from cohort 2. Patients in cohort 1 had event-free survival of 83% at 3.9 ± 0.3 years from the primary endpoints of all-cause mortality, dialysis, and cardiovascular events when treated with interventional therapy, compared to 45% when treated with medical therapy alone (P = .501), which showed a 62% treatment effect for stent placement. In cohort 2, event-free survival rates were 64% for medical therapy versus 52% for medical plus interventional therapy (P = .64). Using Cox regression analysis, the interaction effect between treatment arms and UAlb cohorts was not significant (P = .32). The power of the study to detect an interaction effect, if one existed, was only 15%.Conclusions
Inference cannot be drawn for similar populations because of inadequate sample size, but, in this sample, patients treated with stent placement who had low albuminuria had better outcomes than patients treated with medical therapy alone. 相似文献7.
【目的】观察肾络安方对肥胖型早期糖尿病肾病的治疗效果并探讨其可能的机制。【方法】将68例肥胖型早期糖尿病肾病患者随机分为对照组和治疗组,每组各34例。2组均给予调整生活方式、饮食控制、降压、降糖、降脂等基础治疗,对照组同时给予厄贝沙坦口服,治疗组在对照组基础上加用肾络安方治疗。治疗16周后,比较2组治疗前后中医证候积分、体质量指数(BMI)、血液指标[血胱抑素C(Cys C)、血β2微球蛋白(β2-MG)、同型半胱氨酸(Hcy)、空腹血糖(FBG)]及尿液指标[尿单核细胞趋化蛋白-1/尿肌酐(UMCP-1/UCR)、正常T细胞活化后表达和分泌调节蛋白/尿肌酐(URANTES/UCR)、尿白蛋白—肌酐比值(UACR)、尿白蛋白排泄率(UAER)]的变化情况,并评价其疗效及安全性。【结果】1治疗过程中5例脱落,63例(治疗组32例、对照组31例)完成试验。2治疗组总有效率为90.6%,明显优于对照组的67.7%(P0.05)。3治疗后,2组BMI均较治疗前明显降低(P0.05)。4治疗后,治疗组的各项中医证候积分、血液指标(Cys C、β2-MG、Hcy、FBG)及尿液指标(UMCP-1/UCR、URANTES/UCR、UACR、UAER)均较本组治疗前及对照组治疗后明显降低(P0.05)。5UMCP-1/UCR、URANTES/UCR、UACR、UAER相互呈正相关。6本试验中63例患者治疗前后血常规、大便常规、肝功能、心电图等安全性指标检测均未发现明显异常改变。【结论】肾络安方结合西药治疗肥胖型早期糖尿病肾病具有较好的疗效,可以减轻临床症状,降低BMI、Cys C、β2-MG、UACR、UAER水平,减少UMCP-1、URANTES排泄,其作用机制可能与肾络安方联合西药能抑制肾脏慢性炎症有关。 相似文献
8.
Daniel E. Weiner Meyeon Park Hocine Tighiouart Alin A. Joseph Myra A. Carpenter Nitender Goyal Andrew A. House Chi-yuan Hsu Joachim H. Ix Paul F. Jacques Clifton E. Kew S. Joseph Kim John W. Kusek Todd E. Pesavento Marc A. Pfeffer Stephen R. Smith Matthew R. Weir Andrew S. Levey Andrew G. Bostom 《American journal of kidney diseases》2019,73(1):51-61
9.
多因素干预降低2型糖尿病患者尿白蛋白与肌酐比率 总被引:1,自引:0,他引:1
目的观察为期两年的多因素强化干预治疗对2型糖尿病(T2DM)患者尿白蛋白/肌酐比率(UACR)的影响。方法对102例T2DM患者强化控制血糖、血压和血脂,随访2年,追踪观察强化控制前后的85例患者血糖、血压、血脂、BMI和UACR的变化,并进行相关及回归分析。结果T2DM患者血糖、血压和血脂强化治疗后,UACR降低[(31±26)mg/gvs(44±46)mg/g,P0.05];相关及回归分析显示糖化血红蛋白和收缩压的变化值与UACR变化值呈显著正相关(r值分别为0.507和0.358,P0.05),糖化血红蛋白和收缩压的变化值是影响UACR变化的主要因素。结论血糖、血压及血脂的强化控制,尤其是严格控制糖化血红蛋白及收缩压,能降低T2DM患者的UACR,减低糖尿病并发症发生的风险。 相似文献
10.
Salwa S. Hosny Meram M. Bekhet Hayam A. Hebah Nagwa R. Mohamed 《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2018,12(6):1019-1024